Evaluating the accessibility and capacity of SARS-CoV-2 vaccination and analyzing convenience-related factors during the Omicron variant epidemic in Beijing, China

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-19 DOI:10.1080/21645515.2023.2289250

Yuping Duan, Mingyue Jiang, Luodan Suo, Mingyu Xu, Xiaomei Li, Qing Wang, Chengxu Bai, Jiang Wu, Zheng Xu, Weizhong Yang, Luzhao Feng, Juan Li

引用次数: 0

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination service system lacks standardized indicators to assess resource allocation. Moreover, data on specific vaccination-promo...

查看原文本刊更多论文

在中国北京 Omicron 变种疫情期间评估 SARS-CoV-2 疫苗接种的可及性和能力，并分析与便利性相关的因素

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 疫苗接种服务系统缺乏评估资源分配的标准化指标。此外，有关具体疫苗接种推广活动的数据...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.